A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Phase 2

Not yet recruiting

• Conditions: Head and Neck Neoplasms
• Interventions: Biological: Camrelizumab; Drug: Cisplatin; Radiation: IMRT or VMAT

• Registration Number: NCT04405154
• Lead Sponsor: West China Hospital

Brief Summary

The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Status Verified: 2020-05
• Study First Submitted: 2020-05-22
• Study First Submitted QC: 2020-05-22
• Last Update Submitted: 2020-05-22
• Study First Posted: 2020-05-28
• Last Update Posted: 2020-05-28
• Study Start: 2020-06-01
• Primary Completion: 2023-05-31
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Written informed consent
• Has a pathologically proven new diagnosis of head and neck squamous cell carcinoma
• Has unresectable disease and is eligible for definitive chemoradiation based on investigator decision
• Has Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) based on RECIST version 1.1
• Has adequate organ function as defined
• Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
• Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy

Read More

Exclusion Criteria

• Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer
• Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy
• Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization
• Has a history of severe hypersensitivity reaction to camrelizumab, Cisplatin or radiotherapy
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy
• Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody or has previously participated in clinical studies with camrelizumab
• Has received a live vaccine within 30 days prior to the first dose of study therapy
• Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study
• Has not recovered from major surgery prior to starting study therapy
• Has known active Hepatitis B or C
• Has known history of Human Immunodeficiency Virus (HIV)
• Has a significant cardiovascular disease
• Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment
• Has had previous allogeneic tissue/solid organ transplant
• Has active infection requiring systemic therapy
• Is pregnant or breast feeding

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Investigational Arm	Cisplatin	Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
Investigational Arm	Camrelizumab	Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
Investigational Arm	IMRT or VMAT	Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate	6 months	The number of participants with radiologically confrmed complete or partial response according to RECIST 1.1

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	Up to 5 years	OS is the time from randomization to death due to any cause.
Disease-free Survival (DFS)	Up to 5 years	DFS is the time from the date of randomization to the date of first record of disease recurrence or death.
Acute Adverse Events (AEs)	Up to 6 months	The number of participants who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0